BiotechTubeBiotechTube
Home/Pipeline/Oncology Portfolio

Oncology Portfolio

Various Cancers

Phase 1-3Multiple Active Programs

Key Facts

Indication
Various Cancers
Phase
Phase 1-3
Status
Multiple Active Programs
Company
Pfizer

About Pfizer

Founded in 1849, Pfizer has evolved into a global biopharmaceutical leader with a comprehensive portfolio spanning vaccines, oncology treatments, and medicines for chronic diseases. The company operates extensive R&D programs across four key therapeutic areas and maintains a robust clinical pipeline with programs in all phases of development. Led by CEO Albert Bourla, Pfizer continues to drive innovation through strategic partnerships and significant investments in breakthrough science.

View full company profile

Therapeutic Areas

OncologyInternal MedicineInflammation & ImmunologyVaccinesCardiovascularDiabetesObesity

Other Various Cancers Drugs

DrugCompanyPhase
RetifanlimabEli LillyPhase 2/3
Imfinzi (durvalumab)AstraZenecaApproved
Lynparza (olaparib)MerckCommercial
PD-1 InhibitorAkesoPhase 2/3
Mitoxantrone LiposomeCSPC Pharmaceutical Group LimitedPhase 3
Biosimilar BevacizumabCiplaCommercial
Tazverik (tazemetostat)EisaiCommercial
Oncology GenericsAurobindo PharmaCommercial
Opdivo (nivolumab)Ono PharmaceuticalApproved
Oncology APIs (e.g., Sorafenib, Lenalidomide)Laurus LabsCommercial/Filed
Tumor Marker Portfolio (PSA, CA125, etc.)H.U. Group HoldingsCommercial
Logic-gated Switch-DARPinsMolecular PartnersPreclinical